These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17767433)

  • 21. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A technocratic fix to the "legitimacy problem"? The Blair government and health care rationing in the United Kingdom.
    Syrett K
    J Health Polit Policy Law; 2003 Aug; 28(4):715-46. PubMed ID: 12956521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
    Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
    Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reflections on the evolution of health technology assessment in Europe.
    Sorenson C; Chalkidou K
    Health Econ Policy Law; 2012 Jan; 7(1):25-45. PubMed ID: 22221927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review.
    Löblová O; Trayanov T; Csanádi M; Ozierański P
    Value Health; 2020 Jan; 23(1):3-9. PubMed ID: 31952670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health technology assessment in Ireland.
    Ahern F; O'Doherty N
    Int J Technol Assess Health Care; 2000; 16(2):449-58. PubMed ID: 10932418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
    Buxton M
    Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Regional HTA work can have a good impact on health care. Good examples form Vastra Gotaland].
    Bergh C; Alopaeus E; Jivegård L; Samuelsson O; Sjövall H; Strandell A; Svanberg T
    Lakartidningen; 2010 Jul 21-Aug 10; 107(29-31):1780-3. PubMed ID: 20812564
    [No Abstract]   [Full Text] [Related]  

  • 29. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme research funding and UK burden of disease.
    Chinnery F; Bashevoy G; Blatch-Jones A; Douet L; Puddicombe S; Raftery J
    Trials; 2018 Feb; 19(1):87. PubMed ID: 29394905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Technology Assessment in the UK.
    Raftery J; Powell J
    Lancet; 2013 Oct; 382(9900):1278-85. PubMed ID: 24120204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of health technology assessment.
    Banta D
    Health Policy; 2003 Feb; 63(2):121-32. PubMed ID: 12543525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Cowles E; Marsden G; Cole A; Devlin N
    Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of health technology assessment in China: New challenges.
    Chen Y; He Y; Chi X; Wei Y; Shi L
    Biosci Trends; 2018; 12(2):102-108. PubMed ID: 29760354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. INTEGRATE-HTA: THE PERSPECTIVE OF EUnetHTA.
    Lampe K; Schnell-Inderst P
    Int J Technol Assess Health Care; 2017 Jan; 33(5):605-608. PubMed ID: 28874222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA.
    Huic M; Tandara Hacek R; Svajger I
    Int J Technol Assess Health Care; 2017 Jan; 33(3):376-383. PubMed ID: 28803589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Not NICE: a better way forward?
    Bush A; Lenney W; Spencer D; Warner JO
    Arch Dis Child; 2011 Oct; 96(10):907-8. PubMed ID: 21266342
    [No Abstract]   [Full Text] [Related]  

  • 40. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
    Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
    Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.